Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis

Cell Growth and Differentiation

Volumn 8, Issue 8, 1997, Pages 829-838

  Jones, Jeffrey M ^a   Attardi, Laura ^b   Godley, Lucy A ^c   Laucirica, Rodolfo ^a   Medina, Daniel ^a   Jacks, Tyler ^b   Varmus, Harold E ^c   Donehower, Lawrence A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST TUMOR; CANCER CELL CULTURE; CELL PROLIFERATION; GENE LOSS; GENE MUTATION; GROWTH REGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; CELL DIVISION; CROSSES, GENETIC; DNA, NEOPLASM; FEMALE; GENES, P53; HYPERPLASIA; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; MITOSIS; PROTO-ONCOGENE PROTEINS; WNT PROTEINS; WNT1 PROTEIN; ZEBRAFISH PROTEINS;

ANIMALIA; MUS MUSCULUS;

EID: 0030812202     PISSN: 10449523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Hollstein, M., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sorlie, T., Hovig, E., Smith-Sorensen, B., Montesano, R., and Harris, C. C. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res., 22: 3551-3554, 1994.
2. Greenblatt, M. S., Bennett, W. P., and Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878, 1994.
3. Moll, U. M., Riou, G., and Levine, A. J. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc. Natl. Acad. Sci. USA, 89: 7262-7266, 1992.
4. Moll, U. M., Ostermeyer, A. G., Haladay, R., Winkfield, B., Frazier, M., and Zambetti, G. Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Mol. Cell. Biol., 16: 1126-1130, 1996.
5. Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69: 1237-1245, 1992.
6. Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., and Vogelstein, B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature (Lond.), 358: 80-83, 1992.
7. McCann, A. H., Kirley, A. Carney, D. N., Corbally, N., Magee, H. M., Keating G., and Dervan, P. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br. J. Cancer, 71: 981-985, 1995.
8. Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., and Kastan, M. B. Wildtype p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491-7495, 1992.
9. Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J., Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71: 587-597, 1992.
10. 2-M by p53. Oncogene, 10: 109-115, 1995.
11. 2-M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl. Acad. Sci. USA, 92: 8493-8497, 1995.
12. Cross, S. M., Sanchez, C. A., Morgan, C. A., Schimke, M. K., Ramel, S., Idzerda, R. L., Raskind, W. H., and Reid, B. J. A p53-dependent mouse spindle checkpoint. Science (Washington DC), 267: 1353-1356, 1995.
13. Lu, X., and Lane, D. P. Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell, 75: 765-778, 1993.
14. Di Leonardo, A., Linke, S. P., Clarkin, K., and Wahl, G. M. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev., 8: 2540-2551, 1994.
15. Yonish-Rouach, E., Pesnitzky, D., Lotem, J., Sachs, L., Kimchi, A., and Oren, M. Wild type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature (Lond.), 352: 345-347, 1991.
16. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., and Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (Lond.), 362: 847-849, 1993.
17. Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., and Wyllie, A. H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (Lond.), 362: 849-852, 1993.
18. Midgley, C. A., Owens, B., Briscoe, C. V., Thomas, D. B., Lane, D. P., and Hall, P. A. Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo. J. Cell Sci., 108: 1843-1848, 1995.
19. Chen, X., Ko, L. J., Jayaraman, L., and Prives, C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes & Dev., 10: 2438-2451, 1996.
20. Canman, C. E., Gilmer, T. M., Coutts, S. B., and Kastan, M. B. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev., 9: 600-611, 1995.
21. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
22. Hermeking, H., and Eick, D. Mediation of c-myc-induced apoptosis by p53. Science (Washington DC), 265: 2091-2093, 1996.
23. waf1/cip1. Genes Dev., 8: 2817-2830, 1994.
24. Lowe, S. W., Jacks, T., Housman, D. E., and Ruley, H. E. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc. Natl. Acad. Sci. USA, 91: 2026-2030, 1994.
25. Morgenbesser, S. D., Williams, B. O., Jacks, T., and DePinho, R. A. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature (Lond.), 371: 72-74, 1994.
26. Symonds, H., Krall, L., Remington, L., Saenz-Robles, M., Lowe, S., Jacks, T., and Van Dyke, T. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell, 78: 703-711, 1994.
27. Howes, K. A., Ransom, N., Papermaster, D. S., Lasudry, J. G. H., Albert, D. M., and Windle, J. J. Apoptosis or retinoblastoma: alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53. Genes Dev., 8: 1300-1310, 1994.
28. Pan, H., and Griep, A. E. Temporally distinct patterns of p53-dependent and p53-independent apoptosis during mouse lens development. Genes Dev., 9: 2157-2169, 1995.
29. Kern, S. E., Fearon, E. R., Tersmette, K. W., Enterline, J. P., Leppert M., Nakamura, Y., White, R., Vogelstein, B., and Hamilton, S. R. Clinical and pathological associations with allelic loss in colorectal carcinoma. J. Am. Med. Assoc., 261: 3099-3103, 1989.
30. Harris, C. C., and Hollstein, M. Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med., 329: 1318-1327, 1993.
31. Bischoff, F. Z., Yim, S. O., Pathak, S., Grant, G., Siciliano, M. J., Giovanella, B. C., Strong, L. C., and Tainsky, M. A. Spontaneous abnormalities in normal fibroblasts from patients with Li-Fraumeni cancer syndrome: aneuploidy and immortalization. Cancer Res., 50: 7979-7984, 1990.
32. Livingstone, L. R., White, A., Sprouse, J., Livanos, E., Jacks, T., and Tlsty, T. D. Altered cell cycle arrest and gene amplification potential accompany loss of wild type p53. Cell, 70: 605-620, 1992.
33. Yin, Y., Tainsky, M. A., Bischoff, F. Z., Strong, L. C., and Wahl, G. M. Wild type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell, 70: 937-948, 1992.
34. Harvey, M., Sands, A. T., Weiss, R. S., Hegi, M. E., Wiseman, R. W., Pantazis, P., Giovanella, B. C., Tainsky, M. A., Bradley, A., and Donehower, L. A. In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene, 8: 2457-2467, 1993.
35. Galipeau, P. C., Cowan, D. S., Sanchez, C. A., Barrett, M. T., Emond, M. J., Levine, D. S., Rabinovitch, P. S., and Reid, B. J. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc. Natl. Acad. Sci. USA, 93: 7081-7084, 1996.
36. Soder, A. I., Hopman, A. H. N., Ramaekers, F. C. S., Conradt, C., and Bosch, F. X. Distinct nonrandom patterns of chromosomal aberrations in the progression of squamous cell carcinomas of the head and neck. Cancer Res., 55: 5030-5037, 1995.
37. Kihana, T., Tsuda, H., Teshima, S., Okada, S., Matsuura, S., and Hirohashi, S. High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy. Jpn. J. Cancer Res., 83: 978-984, 1992.
38. Eyfjord, J. E., Thorlacius, S., Steinarsdottir, M., Valgardsdottir, R., Ogmundsdottir, H. M., and Anamthawat-Jonsson, K. p53 abnormalities and genomic instability in primary human breast carcinomas. Cancer Res., 55: 646-651, 1995.
39. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
40. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K., and Elledge, S. J. The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75: 805-816, 1993.
41. Papadopoulos, I., Rudolph, P., Wirth, B., and Weichert-Jacobsen, K. p53 expression, proliferation marker Ki-S5, DNA content and serum PSA: possible biopotential markers. Urology, 48: 261-268, 1996.
42. Nawa, G., Ueda, T., Mori, S., Yoshikawa, H., Fukuda, H., Ishiguro, S., Funai, H., and Uchida, A. Prognostic significance of Ki67 (MIB1) proliferation index and p53 over-expression in chondrosarcomas. Int. J. Cancer, 69: 86-91, 1996.
43. Gelsleichter, L., Gown, A. M., Zarbo, R. J., Wang, E., and Coltrera, M. D. p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors. Mod. Pathol., 8: 530-535, 1995.
44. Sirvent, J. J., Salvado, M. T., Santafe, M., Martinez, S., Brunet, J., Alvaro, T., and Palacios, J. p53 in breast cancer. Its relation to histological grade, lymph-node status, hormone receptors, cell-proliferation fraction (ki-67) and c-erbB-2. Immunohistochemical study of 153 cases. Histol. Histopathol., 10: 531-539, 1995.
45. Tsukamoto, A. S., Grosschedl, R., Guzman, R. C., Parslow, T., and Varmus, H. E. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell, 55: 619-625, 1988.
46. Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Jr., Butel, J. S., and Bradley, A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature (Lond.), 356: 215-221, 1992.
47. Donehower, L. A., Godley, L. A., Aldaz, C. M., Pyle, R., Shi, Y-P., Pinkel, D., Gray, J., Bradley, A., Medina, D., and Varmus, H. E. Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev., 9: 882-895, 1995.
48. Miller, B. E., Miller, F. R., Wiburn, D., and Heppner, G. H. Dominance of a tumor subpopulation in mixed heterogeneous mouse mammary tumors. Cancer Res., 48: 5747-5753, 1988.
49. Kerr, J. F. R., and Harmon, B. V. Definition and incidence of apoptosis: an historical perspective. In: L. D. Tomei and F. O. Cope (eds.), The Molecular Basis of Cell Death, pp. 5-29. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1991.
50. Demirel, D., Laucirica R., Fishman, A., Owens, R. G., Grey, M. M., Kaplan, A. L., and Ramzy, I. Ovarian tumors of low malignant potential. Correlation of DNA index and S-phase fraction with histopathologic grade and clinical outcome. Cancer (Phila.), 77: 1494-1500, 1996.
51. Hundley, J. E., Koester, S. K., Troyer, D. A., Hilsenbeck, S. G., Subler, M. A., and Windle, J. J. Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53. Mol. Cell. Biol., 17: 723-731, 1997.
52. Li, M., Hu, J., Heermeier, K., Hennighausen, L., Furth, P. A. Apoptosis and remodeling of mammary gland tissue during involution proceeds through p53-independent pathways. Cell Growth & Differ., 7: 13-20, 1996.
53. Jue, S. F., Bradley, R. S., Rudnicki, J. A., Varmus, H. E., and Brown, A. M. C. The mouse Wnt-1 gene can act via a paracrine mechanism in transformation of mammary epithelial cells. Mol. Cell. Biol., 12: 321-328, 1992.
54. Bradley, R. S., and Brown, A. M. C. A soluble form of Wnt-1 protein with mitogenic activity on mammary epithelial cells. Mol. Cell. Biol., 15: 4616-4622, 1995.
55. Dameron, K. M., Volpert, O. V., Tainsky, M. A., and Bouck, N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science (Washington DC), 265: 1582-1584, 1994.
56. Van Meir, E. G., Polverini, P., Chazin, V. R., Su Huang, H. J., de Tribolet, N., and Cavenee, W. K. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat. Genet., 8: 171-176, 1994.
57. Thompson, T. C., Park, S. H., Timme, T. L., Ren, C., Eastham, J. A., Donehower, L. A., Bradley, A., Kadmon, D., and Yang, G. Loss of p53 function leads to metastasis in ras + myc-initiated mouse prostate cancer. Oncogene, 10: 869-879, 1995.
58. Hedley, D. W., Friedlander, M. L., Taylor, I. W., Rugg, C. A., and Musgrove, E. A. Method of analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J. Histochem. Cytochem., 21: 1333-1335, 1983.
59. Vindelov, L. L., Christensen, I. J., and Nissen, N. I. A detergent-trypsin method for the preparation of nuclei for flow cylometric DNA analysis. Cytometry, 3: 323-327, 1993.